Target family: Histamine receptors (type: gpcr)
Target: H<sub>4</sub> receptor

Ligand: SENS-111 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Effect of the novel histamine H<sub>4</sub> receptor antagonist SENS-111 on spontaneous nystagmus in a rat model of acute unilateral vestibular loss.
Published in: Br J Pharmacol

Ligand: ST-1006 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.900000095367432 pKi
Reference (Journal): International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
Published in: Pharmacol Rev

Ligand: [125I]CCL16 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.8 pKd
Reference (Journal): Liver-expressed chemokine/CC chemokine ligand 16 attracts eosinophils by interacting with histamine H4 receptor.
Published in: J Immunol

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
Published in: Br J Pharmacol

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.4 pKd
Reference (Journal): Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
Published in: J Pharmacol Exp Ther

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.9 pKd
Reference (Journal): Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
Published in: J Pharmacol Exp Ther

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
Published in: Mol Pharmacol

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
Published in: J Pharmacol Exp Ther

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Discovery of a novel member of the histamine receptor family.
Published in: Mol Pharmacol

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes.
Published in: J Biol Chem

Ligand: [3H]histamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd
Reference (Journal): Cloning and characterization of a novel human histamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: [3H](R)-α-methylhistamine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.2 pKd
Reference (Journal): Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
Published in: Mol Pharmacol

Ligand: [3H]JNJ 7777120 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.4 pKd
Reference (Journal): A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties.
Published in: J Pharmacol Exp Ther

Ligand: [3H]pyrilamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.5 pKd
Reference (Journal): Discovery of a novel member of the histamine receptor family.
Published in: Mol Pharmacol

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning and characterization of a novel human histamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
Published in: J Pharmacol Exp Ther

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
Published in: Mol Pharmacol

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
Published in: J Pharmacol Exp Ther

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
Published in: J Pharmacol Exp Ther

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
Published in: J Pharmacol Exp Ther

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression, and pharmacological characterization of a novel human histamine receptor.
Published in: Mol Pharmacol

Ligand: thioperamide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Published in: Biochem Pharmacol

Ligand: toreforant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pKi
Reference (Patent): Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor

Ligand: VUF 8430 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pKi
Reference (Journal): Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist.
Published in: J Med Chem